Skip To Main Content
Iurii Osipov on Muck Rack

Iurii Osipov

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Iurii Osipov’s profile

Articles by Iurii Osipov

Final analysis results from DREAMM-3, a phase 3 study of belantamab mafodotin versus pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

|
By Meletios Athanasios Dimopoulos, Vânia Hungria, Haitao Meng, Atanas Radinoff, Jian Li, Sosana Delimpasi, Ting Niu, Gábor Mikala, Tamás Masszi, Marcelo Capra, Michael Low, Angelo Maiolino, Yan Xu, Xavier Leleu, Vasiliki Pappa, Dominik Chraniuk, Tatiana Konstantinova, Shawn Hakim, Chris Brawley, Astrid McKeown, Julia Boyle, Sumita Roy-Ghanta, Katja Weisel, Iurii Osipov, Gabriela Tubel
| Nature Verified
To the Editor, Targeting B-cell maturation antigen (BCMA) has transformed the relapsed/refractory multiple myeloma (RRMM) landscape with unprecedented overall survival (OS) outcomes versus standard-of-care triplet regimens. Belantamab mafodotin, an anti-BCMA antibody-drug conjugate, has a multimodal mechanism of action involving minimal immunosuppression and no evidence of induction of T-cell exhaustion [1, 2].
Open in Who Shared Issue with article?
Show More